Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
Clin. transl. oncol. (Print)
; 23(7): 1304-1313, jul. 2021. tab
Artigo
em Inglês
| IBECS
| ID: ibc-221970
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Aim To stablish a consensus on the treatment strategy for advanced nonsmall-cell lung cancer (aNSCLC) with epidermal growth factor receptor mutation (EGFRm) in Spain. Methods After a systematic literature review, the scientific committee developed 33 statements in 4 fields molecular diagnosis (10 items); histologic profile and patient clinical characteristics (7 items); first-line (1L) treatment in EGFRm aNSCLC (8 items); and subsequent-line treatment (8 items). A panel of 31 experts completed 2 Delphi online questionnaires rating their degree of agreement/disagreement for each statement through a 19 range scale (13 = disagree, 79 = agree). Consensus was reached if 2/3 of the participants are in the median range. Results In the first Delphi round consensus was achieved for 24/33 of the statements. One of the assertions was deleted, proceeding to a second round with the eight remaining questions with no consensus or in the range of indeterminacy. Determination of the EGFR status from tissue and analysis of the different biomarkers are two important variables that influenced treatment decision in patients with aNSCLC. 1L treatment should be the best therapeutic option, independently of the subsequent lines of treatment. For patients with the most common activating mutations osimertinib was considered the most efficient and safe 1L option. In case of disease progression, a new biopsy was needed. Conclusions A consensus document is proposed to optimize the treatment strategy for untreated patients with a NSCLC with EGFR sensitizing mutations (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2021
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Santa Creu I Sant Pau/Spain
/
Hospital Universitari I Politècnic La Fe/Spain
/
IIS Aragón/Spain
/
University Hospital A Coruña/Spain
/
University Hospital La Paz-IDIPAZ/Spain
/
University Hospital Virgen Macarena/Spain